MK-4830 + pembrolizumab + pemetrexed + cisplatin

MK-4830 + pembrolizumab + pemetrexed + cisplatin is an investigational combination regimen under clinical evaluation primarily for advanced solid tumors, including non-small cell lung cancer (NSCLC) and mesothelioma. MK-4830 is a first-in-class human IgG4 monoclonal antibody targeting immunoglobulin-like transcript 4 (ILT4), designed to alleviate myeloid-driven immunosuppression in the tumor microenvironment. Pembrolizumab is a programmed cell death 1 (PD-1) immune checkpoint inhibitor. Pemetrexed is a folate antimetabolite chemotherapy agent, and cisplatin is a platinum-based chemotherapeutic. Together, this combination aims to enhance antitumor immunity by concurrently blocking both ILT4 and PD-1 checkpoints and disrupting tumor cell proliferation and survival by cytotoxic chemotherapy. The regimen is administered intravenously in cycles, often as initial therapy for advanced/metastatic non-squamous NSCLC or mesothelioma[1][2][3][7][9]. MK-4830 is developed by Merck and is frequently studied alongside Merck’s pembrolizumab[7].

Brand names

KEYTRUDA (for pembrolizumab)